Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission file number: 001-42408 MEDICUS PHARMA LTD. (Exact Name of Registrant as Specified in Its Charter) | Ontario, Canada | 98-1778211 | | --- ...

In April, Medicus Pharma Ltd. MDCX agreed to acquire all of Antev’s issued and outstanding shares on a share exchange.Antev is a clinical-stage biotech company developing Teverelix, a next-generation GnRH antagonist, as the first in-market product for cardiovascular high-risk prostate cancer patients and patients with first acute urinary retention (AURr) episodes due to an enlarged prostate.Medicus will negotiate and enter into a definitive agreement with Antev in exchange for 2.67 million (or approximately ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to _____ Commission File Number 001-42408 MEDICUS PHARMA LTD. (Exact name of Registrant as specified in its Charter) Ontario, Canada (State or other jurisdicti ...

Exhibit 99.2 Medicus Pharma Ltd. Condensed Consolidated Interim Financial Statements For the three and nine months ended September 30, 2024 and 2023 (unaudited) (expressed in United States dollars, except number of shares) Medicus Pharma Ltd. Condensed Consolidated Interim Statements of Financial Position (unaudited) (expressed in United States dollars) | As at | | September 30, | December 31, | | --- | --- | --- | --- | | | | 2024 | 2023 | | | Notes | $ | $ | | Assets | | | | | Current assets | | | | | Cas ...